ALSO NOTED: FDA OKs Novalar therapy; StemCells files new patent suit; and much more...

> The FDA has OK'd Novalar's OraVerse (phentolamine mesylate) for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic. Novalar release

> StemCells has filed its second patent suit against Neuralstem claiming two human neural stem cells patents were violated. Report

> Takeda and Affymax have posted more positive mid-stage data for their experimental anemia therapy. Release

> Pipex Pharmaceuticals is reporting that the FDA has provided orphan drug status for oral tetrathiomolybdate as a therapy for Idiopathic Pulmonary Fibrosis. Pipex release

> Forest Laboratories and Daiichi Sankyo have ended a co-promotion deal for Azor, a combo therapy of two antihypertensives. Forest release

> Big-name cholesterol meds are losing ground on two fronts. Report

> Politics are clouding the process of tracing contaminated heparin back to its source or sources--politics that go way beyond the typical Democrats-versus-Republicans grandstanding. Report

> With Big Pharma cutting back, CMOs are picking up the slack. The worldwide market for biopharmaceutical contract manufacturing reached $2.4 billion in 2007, a year-over-year leap of 14 percent. CMO report

> Back in 2005, Swedish pharma monitors raised a red flag on GSK's HIV fighter abacavir and its possible link to heart attacks, The Independent is reporting. Report

> According to India-based Dr. Reddy's CEO, the U.S.'s financing industry is "a complete mess." Report

And Finally... Depressed teens that self-medicate with marijuana only trigger more serious mental ailments. Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.